Bristol Myers Squibb’s (BMY) Sotyktu has been approved by the US FDA to treat adults with active psoriatic arthritis (PsA). The approval is based on positive results from two phase 3 trials (POETYK ...

Inizio Ignite has made five appointments to its key leadership amid the unification of four teams, Research Partnership, Putnam, Vynamic and STEM. Remco op den Kelder will continue to lead the ...

Incyte Biosciences UK’s Opzelura (ruxolitinib) cream has been approved for reimbursement for eligible patients with non-segmental vitiligo by the National Institute for Health and Care Excellence ...

As AI drives seismic change across the pharmaceutical industry, its adoption is accompanied by uncertainty and risk.

Commit Biologics, a biotech company pioneering complement system activation, has appointed Thomas Montgomery Andresen as Chief Executive Officer (CEO), effective 16 March 2026. Thomas, a biotech ...

The last patient in Lundbeck’s phase 3 clinical trial, MASCOT, has been randomised ahead of schedule in a study evaluating amlenetug as a potential treatment for multiple system atrophy (MSA). The ...

There’s a clear gap: output is rising, but engagement isn’t. This often happens because many strategies focus on HCPs’ ...

Medical Affairs is operating at a pivotal moment. Expectations have expanded rapidly – deeper scientific exchange, sharper ...

Johnson & Johnson (J&J) has announced US FDA approval for Tecvayli (teclistamab-cqyv) plus Darzalex Faspro (daratumumab and hyaluronidase-fihj) to treat adults with relapsed or refractory multiple ...

Johnson & Johnson’s (J&J) nipocalimab, a potential immunoselective investigational treatment for adults with systemic lupus ...

Bedrock Healthcare Communications is an award-winning, independent agency founded in 2011. We partner with healthcare professionals, patients, and global pharmaceutical and biotech clients to ...

UK biotech N4 Pharma, a company developing a gene delivery system to enable advanced therapies for cancer and other diseases, ...